FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1509238268> ?p ?o ?g. }

• W1509238268 abstract "Epidemiology studies the causes and distribution of population health and disease conditions in defined populations. It identifies risk factors for disease which may help to prevent disease and promote health. Each year, the American Cancer Society describes the epidemiology of cancer in the USA. Breast cancer and CLL are the most common cancers in women and adults, respectively. European data for CLL are limited. For both cancers, chemotherapy is an important treatment option. But side effects such as neutropenia and infections remain the principal dose-limiting toxicities, which may affect the effectiveness of cancer chemotherapy. Several studies evaluated risk factors for chemotherapy-induced neutropenia (CIN; absolute neutrophil count [ANC] <1.5x10^9/L) and febrile neutropenia (FN; ANC <0.5x10^9/L and oral temperature =38° for more than 1 hour): e.g. older age, recent infection, prior chemotherapy, and planned relative dose intensity greater than 85% of standard chemotherapy dosing. The prophylactic use of granulocyte colony-stimulating factors (G-CSFs) has been shown to be protective. Based on the above mentioned risk factors, a number of risk prediction models have been developed over the years. Very often, the risk prediction models considered patient-related, tumour-related, treatment-related, or genetic factors. The majority of these models are not validated using an independent dataset. Systematic reviews of G-CSFs to prevent neutropenia are available, but do not include new long-acting G-CSFs or observational study designs.To address the epidemiology of CLL, the incidence and risk factors of CIN and FN, and to develop and externally validate a risk prediction model for the occurrence of FN including a broad range of risk factors, three quantitative studies were conducted and published. The fourth published study summarised the efficacy, effectiveness and safety of G-CSFs for the prevention of CIN and FN.For the first study, the author conducted a cohort analysis of the UK Clinical Practice Research Datalink (CPRD) to identify the epidemiology of CLL, the incidence of neutropenia, and changes in medical resource utilisation of CLL patients. Due to limited data regarding the incidence of neutropenia, the study focused on the epidemiology of CLL and medical resource utilisation of CLL patients. The incidence of CLL was 6.2 per 100’000 person-years and remained stable between 2006 and 2011. Medical resource utilisation in CLL patients increased over the time period from 2000 to 2012. Primary care data from the UK CPRD seemed to be valid to determine the incidence of CLL. These data may not reflect the total of medical resource use in CLL patients as chemotherapy and treatment of related complications such as infections and neutropenia are mainly performed in secondary or tertiary care.The second study addressed the identification of risk factors and the development of a risk prediction model for FN in a hospital-based breast cancer cohort. Risk factors for FN were lower platelet count and haemoglobin, higher alanine aminotransferase (ALT), and specific allele variants of two single nucleotide polymorphisms (SNPs) in a gene involved in multidrug resistance. Genetic testing beforehand might be helpful to identify patients at a very high risk of FN. Predictive performance of the model was improved by adding genetic information but overall remained limited. The third study used an available risk prediction model for FN in Non-Hodgkin lymphoma (NHL) patients and applied its prediction rules to an independent dataset of NHL patients. Age, weight, baseline white blood cell count, and planned chemotherapy dose were confirmed to predict the risk of FN. However, there was a decrease of the predictive performance in the independent validation dataset. This limits its use in clinical practice. But if successful risk prediction models are developed and externally validated, these may help to optimally target prophylaxis with G-CSFs to those patients at high risk of FN.Finally, a systematic literature review was conducted to identify studies evaluating the efficacy, effectiveness and safety of G-CSFs in the prevention of CIN and FN. Most studies showed better efficacy and effectiveness for the long-acting pegfilgrastim than daily filgrastim. Efficacy and safety profiles of new long-acting G-CSFs such as lipegfilgrastim and balugrastim were comparable to pegfilgrastim. In times of increasing health care costs and scarce resources, the cost-efficient use of supportive measures is necessary.The studies this work is based on showed that the availability of and access to appropriate data sources are necessary to develop and systematically validate risk prediction models. The findings contribute to the development of an evidence-based, efficient and cost-efficient approach to prevent neutropenia in cancer patients." @default.
• W1509238268 created "2016-06-24" @default.
• W1509238268 creator A5064404716 @default.
• W1509238268 date "2015-01-01" @default.
• W1509238268 modified "2023-09-24" @default.
• W1509238268 title "Neutropenia in cancer patients, risk prediction models of neutropenia, and supportive measures" @default.
• W1509238268 cites W1122725800 @default.
• W1509238268 cites W1506645980 @default.
• W1509238268 cites W154377515 @default.
• W1509238268 cites W1568390176 @default.
• W1509238268 cites W1580788756 @default.
• W1509238268 cites W1590066505 @default.
• W1509238268 cites W1601250488 @default.
• W1509238268 cites W1608168342 @default.
• W1509238268 cites W1804059878 @default.
• W1509238268 cites W1901752173 @default.
• W1509238268 cites W1925112136 @default.
• W1509238268 cites W1933165660 @default.
• W1509238268 cites W1964736588 @default.
• W1509238268 cites W1965547591 @default.
• W1509238268 cites W1965581368 @default.
• W1509238268 cites W1965992803 @default.
• W1509238268 cites W1966113759 @default.
• W1509238268 cites W1967553814 @default.
• W1509238268 cites W1968168229 @default.
• W1509238268 cites W1969086628 @default.
• W1509238268 cites W1969840975 @default.
• W1509238268 cites W1970312642 @default.
• W1509238268 cites W1972368700 @default.
• W1509238268 cites W1972405516 @default.
• W1509238268 cites W1972716219 @default.
• W1509238268 cites W1973079966 @default.
• W1509238268 cites W1973734933 @default.
• W1509238268 cites W1974769190 @default.
• W1509238268 cites W1975590576 @default.
• W1509238268 cites W1977924106 @default.
• W1509238268 cites W1979011643 @default.
• W1509238268 cites W1979423827 @default.
• W1509238268 cites W1982414783 @default.
• W1509238268 cites W1982903239 @default.
• W1509238268 cites W1983420484 @default.
• W1509238268 cites W1984901136 @default.
• W1509238268 cites W1986462580 @default.
• W1509238268 cites W1986847248 @default.
• W1509238268 cites W1986983868 @default.
• W1509238268 cites W1988536563 @default.
• W1509238268 cites W1991229588 @default.
• W1509238268 cites W1992911625 @default.
• W1509238268 cites W1993608325 @default.
• W1509238268 cites W1993941594 @default.
• W1509238268 cites W1994160350 @default.
• W1509238268 cites W1995429954 @default.
• W1509238268 cites W1996464306 @default.
• W1509238268 cites W1998637589 @default.
• W1509238268 cites W1998689347 @default.
• W1509238268 cites W1999490101 @default.
• W1509238268 cites W2000445173 @default.
• W1509238268 cites W2000475715 @default.
• W1509238268 cites W2001207261 @default.
• W1509238268 cites W2001368404 @default.
• W1509238268 cites W2001850157 @default.
• W1509238268 cites W2002404007 @default.
• W1509238268 cites W2005826254 @default.
• W1509238268 cites W2008055393 @default.
• W1509238268 cites W2008755622 @default.
• W1509238268 cites W2010627600 @default.
• W1509238268 cites W2010927862 @default.
• W1509238268 cites W2012028554 @default.
• W1509238268 cites W2012234169 @default.
• W1509238268 cites W2014023736 @default.
• W1509238268 cites W2017611339 @default.
• W1509238268 cites W2018503914 @default.
• W1509238268 cites W2018713883 @default.
• W1509238268 cites W2018883183 @default.
• W1509238268 cites W2021411036 @default.
• W1509238268 cites W2022421286 @default.
• W1509238268 cites W2023291563 @default.
• W1509238268 cites W2023344067 @default.
• W1509238268 cites W2023588049 @default.
• W1509238268 cites W2023616083 @default.
• W1509238268 cites W2024933507 @default.
• W1509238268 cites W2025271171 @default.
• W1509238268 cites W2026417873 @default.
• W1509238268 cites W2028454394 @default.
• W1509238268 cites W2028992928 @default.
• W1509238268 cites W2031374290 @default.
• W1509238268 cites W2031497779 @default.
• W1509238268 cites W2031687681 @default.
• W1509238268 cites W2031925819 @default.
• W1509238268 cites W2035842476 @default.
• W1509238268 cites W2036450045 @default.
• W1509238268 cites W2038156351 @default.
• W1509238268 cites W2038182346 @default.
• W1509238268 cites W2038460994 @default.
• W1509238268 cites W2040508660 @default.
• W1509238268 cites W2043921099 @default.
• W1509238268 cites W2043938663 @default.
• W1509238268 cites W2047473984 @default.
• W1509238268 cites W2048982730 @default.
• W1509238268 cites W2049364475 @default.

• next